21814860 25582338 31406111 19397414 18691115 18613849 23998734 26153389 19565906 19660111 18591383 21106069 22567028 20225043 20399959 23123647 19689735 20874652 - Search Results

Year	Number of Results
2008	3
2009	4
2010	4
2011	1
2012	2
2013	1
2015	2
2019	1
2023	0

1

The genetic profiling of preferentially expressed genes in murine splenic CD8α+ dendritic cells.

Li T, Li WY, Bai HL, Ma HB, Zhang H, Zhu JM, Li XH, Huang HY, Ma YF, Ji XY. Li T, et al. Immunol Res. 2011 Oct;51(1):80-96. doi: 10.1007/s12026-011-8237-7. Immunol Res. 2011. PMID: 21814860

2

STAT3 signaling contributes to the high effector activities of interleukin-15-derived dendritic cells.

Okada S, Han S, Patel ES, Yang LJ, Chang LJ. Okada S, et al. Immunol Cell Biol. 2015 May-Jun;93(5):461-71. doi: 10.1038/icb.2014.103. Epub 2015 Jan 13. Immunol Cell Biol. 2015. PMID: 25582338 Free PMC article.

3

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity.

Ray A, Song Y, Chauhan D, Anderson KC. Ray A, et al. Blood Cancer J. 2019 Aug 12;9(8):64. doi: 10.1038/s41408-019-0224-6. Blood Cancer J. 2019. PMID: 31406111 Free PMC article. No abstract available.

4

Novel strategies for improved cancer vaccines.

Chen X, Chang CH, Goldenberg DM. Chen X, et al. Expert Rev Vaccines. 2009 May;8(5):567-76. doi: 10.1586/erv.09.11. Expert Rev Vaccines. 2009. PMID: 19397414 Review.

5

Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.

Bernard MP, Bancos S, Sime PJ, Phipps RP. Bernard MP, et al. Curr Pharm Des. 2008;14(21):2051-60. doi: 10.2174/138161208785294654. Curr Pharm Des. 2008. PMID: 18691115 Free PMC article. Review.

6

CD4+ T-regulatory cells: toward therapy for human diseases.

Allan SE, Broady R, Gregori S, Himmel ME, Locke N, Roncarolo MG, Bacchetta R, Levings MK. Allan SE, et al. Immunol Rev. 2008 Jun;223:391-421. doi: 10.1111/j.1600-065X.2008.00634.x. Immunol Rev. 2008. PMID: 18613849 Review.

7

Immunotherapy strategies for multiple myeloma: the present and the future.

Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA. Locke FL, et al. Immunotherapy. 2013 Sep;5(9):1005-20. doi: 10.2217/imt.13.97. Immunotherapy. 2013. PMID: 23998734 Free PMC article. Review.

8

Immunotherapy for multiple myeloma: Current status and future directions.

Ayed AO, Chang LJ, Moreb JS. Ayed AO, et al. Crit Rev Oncol Hematol. 2015 Dec;96(3):399-412. doi: 10.1016/j.critrevonc.2015.06.006. Epub 2015 Jun 28. Crit Rev Oncol Hematol. 2015. PMID: 26153389 Review.

9

Immunity of lentiviral vector-modified dendritic cells.

Han S, Chang LJ. Han S, et al. Methods Mol Biol. 2009;542:245-59. doi: 10.1007/978-1-59745-561-9_13. Methods Mol Biol. 2009. PMID: 19565906

10

Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications.

Han S, Huang Y, Liang Y, Ho Y, Wang Y, Chang LJ. Han S, et al. J Hematol Oncol. 2009 Aug 6;2:34. doi: 10.1186/1756-8722-2-34. J Hematol Oncol. 2009. PMID: 19660111 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results